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ABSTRACT 
Introduction. Kaczyńska et al. reported a family with myoclonus-dystonia (M-D) caused by a truncating SGCE mutation, in 
which two members had epilepsy. Further, patients had mild psychiatric and developmental deficits. 
Clinical reflections. Characteristic motor features of M-D include myoclonus, dystonia and tremor. A wide range of additional 
disease manifestations are known. A few patients with M-D have seizures. 
Clinical implications. Altered neuronal excitability has been found in the pathogenesis of M-D. This may explain the partial 
effectiveness of antiepileptics and a lower seizure threshold, and could encourage trials of other membrane stabilisers. Careful 
clinical observations of seemingly well-known diseases remain important. 
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In this edition of the Polish Journal of Neurology and Neuro-
surgery, Dr. Kaczyńska et al. report the case of a Polish family 
with myoclonus-dystonia (M-D) and a novel truncating 
mutation in the gene for epsilon-sarcoglycan (SGCE) [1]. 
Six members of the family were affected by upper-body-pre-
dominant myoclonic jerks, dystonia, and/or tremor, such as 
classically characterise this disorder [2,  3]. Age at onset was 
between 18 months and 35 years.  Genetic analyses showed 
a deletion of four bases in exon 7 of the SGCE gene that is 
predicted to cause a premature stop codon. This variant has 
never been reported previously from M-D patients, and is not 
included in the gnomAD database. 
The authors’ careful clinical assessment of the patients 
highlights the fact that non-motor symptoms can be pro-
minent in M-D: two siblings with symptom onset at 1.5 and 
2.5 years showed obsessive-compulsive behaviours, dyslexia 
and dysgraphia, as well as generalised epilepsy with absence 
seizures. One patient underwent a psychological assessment 
as a teenager because of difficulties at school. Although overall 
intellectual abilities were within the normal range, arithmetic 
reasoning, direct auditory memory and long-term memory 
were decreased. The sibling had below average intellectual 
abilities on psychological assessment. Additional work-up 
included a slight reduction of metabolism in medial temporal 
lobes on FDG-PET. 
Variants in SGCE were reported as being the cause of 
M-D in 2001. This enabled the delineation of this syndrome, 
the establishment of diagnostic criteria, and research into its 
underlying pathomechanisms [2–5]. Studies on larger numbers 
of patients have identified obsessive compulsive disorder and 
social and speciﬁc phobias to be recurrent psychiatric features 
[6, 7], and psychosis may occur [4]. 
Interestingly, Kaczyńska et al. also report generalised 
epilepsy with absence seizures in two siblings. Although the 
great majority of M-D patients do not have epilepsy, there 
have been previous reports on seizures in M-D patients (Tab. 
1), and a causal association has been discussed [8–12]. This is 
supported by the findings of altered membrane excitability in 
M-D patients in neurophysiological studies [13, 14]. 
Furthermore, Kaczyńska et al. found mild clinical signs of 
atrophy of head and neck muscles, and frequent choking, in 
one of the patients. Mutations in the other sarcoglycans can 
cause limb girdle muscular dystrophies. However, a previous 
study of six unrelated M-D patients showed no structural 
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Table 1. Reports in the literature on epileptic seizures in M-D. Additionally, seizures during alcohol withdrawal have been described [12]
Publication  
(First author, year,  
reference)
Number of patients  
with M-D and epilepsy  
in family*
Description of seizures SGCE variant as 
reported
Foncke 2003 [9] Three of four affected muta-
tion carriers*
Absence and partial complex seizures with or without secon-
dary generalisation, in one patient preceded by strange feeling 
in stomach
c.885Tins, truncating 
at amino acid posi-
tion 297 
O’Riordan 2004 [11] Two of three affected muta-
tion carriers*
Complex partial seizures with or without secondary generalisa-
tion, preceded by experience of a pungent smell. Lip smacking
c.289C>T, 
p.(Arg97Ter)
Haugarvoll 2014 [10] Four of six affected mutation 
carriers*
Febrile, absence and generalised tonic-clonic seizures c.372delG, 
p.(Lys125SerfsTer7)
Kaczyńska 2020 [1] Two of three affected muta-
tion carriers*
Generalised epilepsy with absence seizures c.806-809delACTG, 
truncating
*Figures include only individuals examined clinically and genetically in the study
changes in biopsies from proximal lower or upper skeletal 
muscles, or cardiac muscle [15]. This is in line with the normal 
creatine kinase and histopathological muscle examination (al-
beit for practical reasons taken from the clinically unaffected 
vastus medialis) in the patient from the Polish family. Although 
molecular characterisation of sarcoglycan complexes from 
skeletal muscle have revealed important differences to those 
found in the brain [16], it cannot be excluded that some M-D 
patients may have atrophy in specific musculature in the head 
and neck that is not easily accessible for biopsy. Or it may be 
that disturbances of membrane excitability also may affect 
muscle function in this disorder [13]. 
We compared Dr. Kaczyńska et al.’s findings with those 
of our patients with M-D. In one family with M-D and a pre-
viously reported [17] heterozygous missense variant SGCE 
c.812G>A p.(Cys271Tyr) in exon 6, the index patient had 
involuntary jerky head and arm movements from the age of 
five, and developed cervical dystonia. Neuropsychological 
evaluation revealed pronounced fatigability, reduced working 
memory, difficulty in concentrating, increased sensibility 
to stress, marked anxiety, and depressive symptoms. When 
tested at age 36, the patient made mistakes in alphabetical 
ordering, which might indicate similar learning deficits as 
in the Polish family [1]. A sibling had myoclonus since the 
age of six, cervical and arm/hand dystonia, and developed 
anxiety and depression. The myoclonic jerks were triggered 
by sudden unexpected sounds startling the patient, who had 
consequently adapted strategies to avoid situations where 
sudden noises can occur, trying to stay in control of their 
surroundings. This had led to a degree of social isolation, 
and might be interpreted as obsessive behaviour observed 
in M-D. There were no cognitive deficits in test batteries. 
The patient experienced difficulties in initiating swallowing, 
but no choking as in the Polish patient, and a mild stutter. 
Evaluation by an otolaryngologist and speech therapist, in-
cluding a fibre-endoscopic laryngeal examination, showed 
oral motor difficulties and late initiation of swallowing, but 
a normal pharyngeal reflex. Palate and tongue root were 
normal shape. A DBS-operation (bilaterally in GPi) improved 
motor symptoms in both siblings, and the male patient has 
become less socially isolated [18, 19]. 
In a second family, a patient had hand tremor, writer’s 
cramp, and pronounced psychiatric disorder with schizoaffec-
tive symptomatology. This patient’s sibling reportedly had mild 
intellectual disability, tremor in limbs, and myoclonic jerks in 
the neck. Both siblings and their asymptomatic father carried 
a different SGCE mutation, a heterozygous 14kb microdeletion 
encompassing the entire exon 6 (NM_001099401,uc003unm.2). 
Their father’s mother reportedly had neurological symptoms, 
compatible with the known maternal imprinting mechanism 
in M-D. No patient in either of these two families reported 
seizures or displayed any obvious amyotrophy. 
The molecular pathogenesis of the wide spectrum of 
neurological and psychiatric manifestations of M-D rema-
ins incompletely understood. Epsilon-sarcoglycan is found 
in membranes of neurons and muscle cells [20] and it has 
previously been suggested that the mechanism behind M-D 
may more closely resemble that of a disturbance in an ion 
channel than that of other forms of dystonia [14]. Careful 
clinical observations, like the study by Kaczyńska et al., can 
stimulate research into the underlying cellular and subcellular 
mechanisms, with the aim of improving clinicians’ ability to 
treat the various manifestations of this disorder. 
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